News

Harvard Bioscience Schedules Second Quarter 2023 Earnings Conference Call for August 8, 2023 at 8:00 AM ET

HOLLISTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the…

1 year ago

Genmab Updates 2023 Financial Guidance

Company Announcement COPENHAGEN, Denmark; July 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its preliminary first half 2023 financial…

1 year ago

Center for Autism & Related Disorders, LLC. – CARD® Receives Court Approval of Sale to Pantogran LLC, Proud Moments ABA, and New Story

Pantogran, LLC, led by Founder Dr. Doreen Granpeesheh, to Acquire 112 CARD Centers and All CARD Intellectual Property Proud Moments ABA…

1 year ago

Small Pharma Reports Fiscal First Quarter 2024 Highlights

• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an…

1 year ago

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD1)…

1 year ago

Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update

NOVATO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development…

1 year ago

SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®

Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current…

1 year ago

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit at €9.3 million3 as of…

1 year ago

Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock

BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel…

1 year ago

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,…

1 year ago